These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23666322)

  • 1. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz.
    McCance-Katz EF; Gruber VA; Beatty G; Lum PJ; Rainey PM
    J Addict Med; 2013; 7(4):264-70. PubMed ID: 23666322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Untreated HIV infection is associated with higher blood alcohol levels.
    McCance-Katz EF; Lum PJ; Beatty G; Gruber VA; Peters M; Rainey PM
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):282-8. PubMed ID: 22495786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
    Gandhi M; Mwesigwa J; Aweeka F; Plenty A; Charlebois E; Ruel TD; Huang Y; Clark T; Ades V; Natureeba P; Luwedde FA; Achan J; Kamya MR; Havlir DV; Cohan D;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):578-84. PubMed ID: 24135775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.
    McCance-Katz EF; Gruber VA; Beatty G; Lum P; Ma Q; DiFrancesco R; Hochreiter J; Wallace PK; Faiman MD; Morse GD
    Am J Addict; 2014; 23(2):137-44. PubMed ID: 24118434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
    King JR; Acosta EP; Yogev R; Wiznia A; Kraimer J; Graham B; Carey V; Britto P; Jean-Philippe P; Moye J; Watson D
    Pediatr Infect Dis J; 2009 Feb; 28(2):159-61. PubMed ID: 19106779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
    Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
    Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
    Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
    BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
    Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
    Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
    Bartelink IH; Savic RM; Mwesigwa J; Achan J; Clark T; Plenty A; Charlebois E; Kamya M; Young SL; Gandhi M; Havlir D; Cohan D; Aweeka F
    J Clin Pharmacol; 2014 Feb; 54(2):121-32. PubMed ID: 24038035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
    Dumond JB; Chen J; Cottrell M; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
    CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):128-135. PubMed ID: 28032946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
    Pillai VC; Parise RA; Christner SM; Rudek MA; Beumer JH; Venkataramanan R
    J Clin Pharmacol; 2014 Nov; 54(11):1272-9. PubMed ID: 24846165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Pillai VC; Venkataramanan R; Parise RA; Christner SM; Gramignoli R; Strom SC; Rudek MA; Beumer JH
    Drug Metab Dispos; 2013 Oct; 41(10):1843-51. PubMed ID: 23913028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
    Teicher E; Vincent I; Bonhomme-Faivre L; Abbara C; Barrail A; Boissonnas A; Duclos-Vallée JC; Taburet AM; Samuel D; Vittecoq D
    Clin Pharmacokinet; 2007; 46(11):941-52. PubMed ID: 17922559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.